According to industry veterans Michelle Berrey, MD, MPH, and Claudia Christian, quality data is the cornerstone for a successful outbreak response plan.
- Data to gauge the level of preparedness, so we can scale the need for medical countermeasures, ICU usage and patient care.
- Data from testing, to track the impact of outbreaks and assess the effectiveness of vaccines and treatments.
- Data for tracking, so we know when we can confidently ease restrictions and get economies moving again.
Experts around the world have thoroughly studied previous outbreaks and pandemics — there have been five pandemics in the last 100 years. Join us for a free webinar with expert leadership to review lessons learned from previous outbreaks and discuss how those lessons should be applied to the current COVID-19 context for a coordinated, proactive and successful response.
You will walk away with a better understanding of:
- The types of data that are critical to understanding and responding to novel infectious diseases
- How different approaches or definitions of data types present challenges in capturing the true situation
- The importance of collaboration across borders and disciplines to collect and disseminate the critical data
About the Presenters
Former President & CEO, Chimerix, Inc. (Nasdaq: CMRX)
Michelle Berrey, MD, MPH, is an experienced public health and infectious disease physician with proven innovation and success in antiviral drug development. Her career in drug development has focused on developing oral antivirals for hepatitis C, HIV, herpesviruses and smallpox. Public-private partnerships have been a cornerstone of Michelle’s career, evidenced by joint trial designs with NIH in HCV in 2009, with WHO and MSF for ebola in 2014 and with BARDA for the first dual-use medical countermeasure for smallpox.
As president and CEO of Chimerix, she led development of the company’s lead product candidate, brincidofovir, an antiviral investigated for the treatment of smallpox, life-threatening adenovirus and ebolavirus infections.
Dr. Berrey received her MD from the Medical College of Georgia and a Master of Public Health from Emory University. She completed her internship and residency in Internal Medicine at the University of North Carolina at Chapel Hill, and was a Senior Fellow in Infectious Diseases at the University of Washington, Seattle, where she conducted research in HIV transmission and acute HIV infection. She is Board Certified in Internal Medicine and Infectious Diseases.
Senior Vice President, Clinical Operations, FHI Clinical
With more than 25 years of experience, Claudia Christian has held positions in pharmaceutical, biotech and CRO industries across multiple indications. Since 2014, she has devoted her expertise full-time to infectious disease research, including managing multiple study protocols and developing sites across West Africa during the Ebola outbreak response. Since that time, she has managed millions of dollars in federally and privately funded grants as well as commercially funded vaccine and other therapeutic studies.
As Senior Vice President, Clinical Operations, Claudia leads the overall direction and strategic implementation of program execution for all clinical research activities at FHI Clinical.
Claudia holds a bachelor’s degree in Biology from Trinity College-Hartford and a master’s certification in Education from Saint Joseph College.
About the Moderator
Senior Director, Global Site Management, FHI Clinical
Twanna Davis is responsible for setting the overall direction, strategy and performance standards for international clinical research activities, including planning, executing, monitoring and reporting on international clinical trials. Davis leads and mentors FHI Clinical’s diverse international clinical monitoring team while maintaining the appropriate resources to meet contractual obligations and ensure adherence to quality management practices. She provides oversight to ensure that the organization and the conduct of regulatory and non-regulatory clinical programs comply with policies and procedures, Regulatory Authority requirements and guidelines, and International Conference on Harmonization (ICH) guidelines in support of global business objectives.
Davis brings a total of 18 years of clinical research experience and a commitment to changing the world through innovation to her role at FHI Clinical. For the past seven years, she has been an adjunct faculty member at Campbell University’s College of Pharmacy and Health. She previously served as Principal Process Owner-Project Services at Rho, where she wrote company-wide processes to assist with Trial Master File compliance standards across functional areas. Prior to joining Rho, she served as Senior Director of Clinical Operations, Global Clinical Monitoring Services at Premier Research, where she provided operational and strategic oversight for several countries.
Davis holds a bachelor’s degree from the University of North Carolina at Wilmington, as well as a master’s degree in Project Management and an MBA from DeVry University.
